The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe. The management of retinopathy of prematurity (ROP) ...
An expert details practical imaging and counseling strategies for slowing vision loss in geographic atrophy through case-based management and patient engagement. Dr. Deepak Sambhara kicks off a ...
Ashkan Abbey, MD, FASRS, FAAO, from Texas Retina Associates discussed EYP-1901, an innovative intravitreal insert that releases vorolanib, a potent tyrosine kinase inhibitor designed to treat retinal ...
Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...
In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...
Neurotech Pharmaceuticals performs the first ENCELTO procedure. Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the first and only ...
Nimesh A. Patel, MD, FASRS, from Mass Eye and Ear Hospital and Boston Children's Hospital presented a real-world study using the Vestrum database to examine usage trends for pegcetacoplan and ...
Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025. The American Society of Retina Specialists (ASRS) is holding their 2025 ...
Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025. To strengthen Opus Genetics’ gene therapy program ...
EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...
The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...
Retinal imaging and the future of early Alzheimer diagnosis. Johnson, MD; Sandra S. Stinnett, DrPh; Dilraj Grewal, MD, FASRS; and Sharon Fekrat, MD, FACS, FASRS, whose mentorship and guidance were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback